

Zinc enhances chemosensitivity to paclitaxel in PC-3 prostate cancer cells

PING ZHANG^{1,2}, YANG LI¹, XINYU TANG¹, RUI GUO¹, JIULING LI¹, YING YING CHEN¹,
HUA GUO¹, JING SU¹, LIANKUN SUN¹ and YANAN LIU¹

¹Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Center,
School of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021;

²Department of Basic Medical Sciences, Medical School, Xiangyang Vocational and Technical College,
Xiangyang, Hubei 441050, P.R. China

Received December 16, 2017; Accepted July 23, 2018

DOI: 10.3892/or.2018.6622

Abstract. Paclitaxel-based chemotherapy is a promising approach for prostate cancer treatment. However, single-drug chemotherapy is associated with an increased risk of drug resistance. Therefore, novel combination chemotherapy regimens are a popular topic of research. Zinc participates in the regulation of apoptosis, for example in the form of Zn^{2+} and via zinc-dependent enzymes. Zinc can either induce or suppress apoptosis, and its effect depends primarily on its concentration. Previous research has demonstrated that physiological concentrations of zinc can directly induce apoptosis of PC-3 prostate cancer cells via the mitochondrial pathway. In prostate cancer tissues, zinc concentrations have been demonstrated to be reduced compared with non-cancerous tissues. Furthermore, the concentration of zinc has been demonstrated to decrease further with cancer progression. In the present study, it was investigated whether exposure of PC-3 cells to zinc improved their sensitivity to the chemotherapeutic agent, paclitaxel. MTT assays, cell clone formation assays, Hoechst staining and flow cytometry revealed that zinc enhanced PC-3-cell chemosensitivity to paclitaxel. Western blotting and reverse transcription-polymerase chain reaction were used to determine that the mitochondria-mediated apoptosis signaling pathway is involved with zinc/paclitaxel-induced cell death. The present study provides a foundation for the development of novel tumor combination therapy.

Introduction

Prostate cancer is among the most common types of cancer in elderly men, and is a leading cause of cancer-associated mortality in Western countries (1). Treatment strategies for prostate cancer include surgery, hormone therapy, radiotherapy and chemotherapy (2). Chemotherapy serves an important role in the treatment of castration-resistant metastatic prostate cancer (3). Paclitaxel has been demonstrated to result in significant antitumor responses in combination with other agents (4,5). However, there are limitations to chemotherapy, including the development of drug resistance, particularly multidrug resistance (6). Therefore, the identification of effective mechanisms to prevent chemotherapy resistance is essential.

The mechanism by which paclitaxel acts on prostate cancer cells is different from the mechanisms of action of other anticancer drugs, and it functions by inhibition of cytoplasmic microtubule depolymerization (7). This inhibits normal spindle formation and causes cell cycle arrest in the G2/M phase (8). Other studies have suggested that the main mechanism by which paclitaxel acts on prostate cancer cells is via Bcl-2 degradation, which reduces the DNA-protective effect of Bcl-2. This results in DNA cleavage into fragments by nucleic acid enzymes, and ultimately leads to apoptosis (9,10).

Zinc is essential for maintaining the integrity of various enzymes and transcription factors (11). Zinc also serves an important role in gene stability and expression (12). In patients with prostate cancer, zinc concentrations have been demonstrated to be reduced by 60-70% in blood serum and cancerous prostate tissue, and to decrease further as cancer progresses (13,14). Another study reported that zinc ions are involved in tumor occurrence and progression (15), and a decline in the concentration of zinc in the serum and tissues has been observed in patients with various types of malignant tumor, including liver, gallbladder, gastrointestinal tract, blood and prostate cancers (16,17).

Under androgen stimulation, the peripheral zone of the prostate exhibits high zinc concentrations (18). In prostate cancer, epithelial cells lose the ability to absorb high concentrations of zinc, and tumor growth increases zinc consumption,

Correspondence to: Mrs. Yanan Liu, Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Center, School of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun, Jilin 130021, P.R. China
E-mail: ynliu@jlu.edu.cn

Key words: zinc, paclitaxel, prostate cancer, chemosensitivity

thus resulting in decreased zinc content (19,20). Previous studies have suggested that physiological concentrations of zinc can directly induce prostate cancer cell apoptosis via the mitochondrial pathway, release of mitochondrial cytochrome *c* and activation of the apoptosis-associated protease caspase-3, which triggers programmed cell death (9,21). Previously, researchers have injected zinc into prostate tumors and found that it inhibited cell growth and prolonged patient survival. Furthermore, treatment with paclitaxel alone has been demonstrated to be associated with the development of drug resistance (22,23). We hypothesized that reduced zinc concentrations may be associated with chemotherapy resistance in prostate cancer. In the present study, it was assessed whether zinc increased chemosensitivity of PC-3 cells to paclitaxel.

Materials and methods

Cell cultivation. PC-3 cells were obtained from the Prostate Diseases Prevention and Treatment Research Center (Jilin University, Changchun, China) and were cultured in Iscove's modified Dulbecco's medium (IMDM; HyClone; GE Healthcare Life Sciences, Little Chalfont, UK) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences) and penicillin-streptomycin (1,000 $\mu\text{g/ml}$). After 48-72 h, the cells were passaged by digestion with 0.25% EDTA-free trypsin (Sangon Biotech Co., Ltd., Shanghai, China) and re-seeded at one third of the previous density. When the cells reached 70-75% confluency, 0, 50, 100, 150, 200, 250, 300, 350, 400 or 450 $\mu\text{mol/l}$ zinc (Sigma-Adrich; Merck KGaA, Darmstadt, Germany) and 0, 2.5, 5, 10, 20, 40, 60 or 80 nmol/l paclitaxel (Harbin Pharmaceutical Group Holding Co., Ltd., Harbin, China) were added. Cells were then collected for analysis of cell activity, apoptosis, mitochondrial membrane potential and protein and gene expression levels.

MTT assay. PC-3 cells were seeded in a 96-well plate at approximately 8×10^3 cells/well and incubated at 37°C in 5% CO₂. After 24 h, when the cells had reached 70-75% confluency, 0, 50, 100, 150, 200, 250, 300, 350, 400 or 450 $\mu\text{mol/l}$ zinc chloride and 0, 2.5, 5, 10, 20, 40, 60 or 80 nmol/l paclitaxel were added. The cells were incubated for a further 48 h, then 20 μl of MTT (Sangon Biotech Co., Ltd., Shanghai, China) was added per well. After 4 h, 150 μl dimethyl sulfoxide (Sangon Biotech Co., Ltd., Shanghai, China) was added to each well to dissolve the formazan crystals, and the absorbance was measured at a wavelength of 490 nm (A490) using a microplate reader (Sangon Biotech Co., Ltd., Shanghai, China).

Cell clone formation assay. A total of 4 groups of cells were prepared: Control group, zinc-treated group, paclitaxel-treated group and zinc+paclitaxel-treated group. Cells were seeded in 6-well plates (500 cells/well; 3-wells/group). The culture medium was replaced every 48 h. Colony formation was observable after 14 days of continuous culture. The culture medium was then removed, and the cells were washed twice with PBS and fixed in 4% formaldehyde for 30 min at room temperature. The fixed cells were subjected to Giemsa staining (Rapid Giemsa staining kit; Sangon Biotech Co., Ltd., Shanghai, China) for 20 min at room temperature, and cell colonies with a diameter >1 mm were counted.

Immunofluorescence. PC-3 cells were seeded in 24-well plates at 5×10^4 cells/well onto a glass coverslip. Following cell adherence, they were exposed to different treatment conditions. After 4 h, the cells were fixed with 4% paraformaldehyde at room temperature for 10-15 min, then washed 2-3 times with 0.1 M PBS. The cells were then incubated with 0.1% Triton for 6-10 min, and washed thrice for 1 min with 0.01 M PBS. The cells were incubated with 5% non-immune bovine serum albumin (HyClone; GE Healthcare Life Sciences, Little Chalfont, UK) to prevent nonspecific binding, then with a Ki-67 primary antibody (dilution, 1:1,000; cat. no. 27309-1-AP; ProteinTech Group, Inc. Chicago, IL, USA) at 37°C for 30 min. Following incubation with a goat anti-rabbit horseradish peroxidase-conjugated IgG secondary antibody (dilution, 1:1,000; cat. no., SA00001-2; ProteinTech Group, Inc. Chicago, IL, USA) at room temperature for 40 min, the cells were stained with Hoechst 33342 (1 $\mu\text{g/ml}$; Sangon Biotech Co., Ltd., Shanghai, China) for 2 min at room temperature, then mounted using aqueous mounting media (glycerin and water, 9:1). Cell staining was detected by fluorescence microscopy at $\times 1,200$, magnification.

Flow cytometric analysis of cell apoptosis. Following exposure of PC-3 cells to different treatment conditions (control group; 250 $\mu\text{mol/l}$ zinc group; 10 nmol/l; paclitaxel group, and 250 $\mu\text{mol/l}$ zinc + 10 nmol/l paclitaxel group) for 48 h, they were washed twice with PBS, then collected using EDTA-free trypsin. The cells were collected by centrifugation at 1,000 \times g for 5 min at 4°C. Annexin V-FITC (5 μl ; Beckman Coulter Inc., Brea, CA, USA) was added and the cells were incubated in the dark for 15 min at 4°C, then 10 μl of propidium iodide (PI; Beckman Coulter Inc.) was added and the cells were incubated in the dark for a further 5 min at 4°C. An Epics-XL-MCL flow cytometer (Beckman Coulter, Inc., Brea, CA, USA) was used to detect the rate of cell apoptosis within 1 h of staining.

Flow cytometric analysis of mitochondrial membrane potential. Around 2.7×10^5 cells/well were cultured in 6-well plates. The cells were collected for flow cytometric analysis by washing twice with PBS, followed by treatment with 0.25% EDTA-free trypsin and centrifugation at 900 \times g for 5 min at 4°C. Serum-free IMDM (1 ml) and JC-1 (1 μl ; Beckman Coulter Inc.) were added and the cells were incubated at 37°C for 20 min, then centrifuged at 1,500-2,000 \times g for 5 min. The culture medium was discarded and the cells were washed twice with PBS, and centrifuged at 2,000 \times g for 5 min. Finally, the cells were resuspended in 400 μl IMDM. Mitochondrial membrane potential was analyzed using an Epics-XL-MCL flow cytometer.

Reverse transcription PCR (RT-PCR). mRNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's protocol. PC-3 cells were cultured in a 6-well plate and harvested by washing twice with PBS, 500 μl TRIzol was added per well and incubated at room temperature for 5 min. The cells were transferred to RNase-free Eppendorf tubes and trichloromethane was added prior to centrifugation.

Table I. Primer sequences used reverse transcription-polymerase chain reaction analysis.

Gene	Forward primer sequence	Reverse primer sequence
GAPDH	5'-AGAAGGCTGGGGCTCATTTG-3'	5'-AGGGGCCATCCACAGTCTTC-3'
Bcl-2	5'-GACTTCGCCGAGATGTCCAGC-3'	5'-GCGTTACGATCGCCTCCATCA-3'
Bax	5'-CGGCGAATTGGAGATGA ACTG-3'	5'-AGCAAAGTAGAAGAGGGCAACC-3'
Caspase-9	5'-GGCCCTTCCTCGCTTCATCTC-3'	5'-GGTCCTTGGGCCTTCCTGGTAT-3'
Caspase-3	5'-ATGGACAACAACGAAACCTCCGTG-3'	5'-CCACTCCCAGTCATTCTTTTAGTG-3'

Bax, Bcl-2 associated X, apoptosis regulator.

Table II. Polymerase chain reaction thermocycling conditions.

Gene	Denaturation	Annealing	Extension	Number of cycles
GAPDH	94°C, 30 sec	55°C, 30 sec	72°C, 30 sec	28
Bcl-2	94°C, 30 sec	55°C, 30 sec	72°C, 30 sec	30
Bax	94°C, 30 sec	54°C, 30 sec	72°C, 30 sec	30
Caspase-9	94°C, 30 sec	55°C, 30 sec	72°C, 30 sec	28
Caspase-3	94°C, 30 sec	56°C, 30 sec	72°C, 30 sec	28

Bax, Bcl-2 associated X, apoptosis regulator.

Isopropanol (cat. no., A507048; Sangon Biotech Co., Ltd.) was added to the aqueous phase at room temperature for 5 min. Finally, RNA was washed in 75% ethanol and resuspended in RNase-free water. Reverse transcription was conducted using Promega M-MLV reverse transcriptase (Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's instructions. PCR was conducted using 2X EasyTaq PCR SuperMix (cat. no. AS111-02; Beijing Transgen Biotech Co., Ltd., Beijing, China). The primer sequences and thermocycling conditions are presented in Tables I and II. The images were captured using the Tanon, 1600R image processing system (Tanon Science and Technology Co., Ltd., Shanghai, China). The gray ratio between the target genes and GAPDH was analyzed to measure the expression level of target genes by image processing system (Tanon, 1600R; Tanon Science and Technology Co., Ltd.).

Western blotting. PC-3 cells were lysed by incubation with 100-150 μ l of radioimmunoprecipitation assay buffer supplemented with phenylmethylsulfonyl fluoride (Roche Diagnostics, Basel, Switzerland), then sonicated 3-5 times for 3-4 sec using ultrasound pyrolysis apparatus (Tomy Seiko Co., Ltd., Tokyo, Japan). Subsequently, the cells were centrifuged at 12,000 \times g, for 20 min at 4°C and the protein concentration was measured using Bradford reagent (BioRad Laboratories, CA, USA). The lysates were subjected to 12% SDS-PAGE and transferred onto polyvinylidene fluoride membranes (EMB Millipore, Billerica, MA, USA). The membranes were washed with TBS-Tween (Sangon Biotech Co., Ltd.) on the horizontal rocking bed 3 times for 5 min, and then blocked with 5%

skimmed milk (Sangon Biotech Co., Ltd.) on the horizontal rocking bed for 1 h at room temperature. Bcl-2-associated X, apoptosis regulator (Bax), Bcl-2, caspase-3, caspase-9, cleaved caspase-3 and cleaved caspase-9 were detected by western blotting. Bax (dilution, 1:1,000; cat. no., 23931-1-AP) and Bcl-2 (dilution, 1:1,000; cat. no. 12789-1-AP) primary antibodies were purchased from ProteinTech Group, Inc. (Chicago, IL, USA). Cleaved caspase-3 (dilution, 1:1,000; cat. no., 9664), cleaved caspase-9 (dilution, 1:1,000; cat. no., 9509), caspase-3 (dilution, 1:1,000; cat. no., 9662), caspase-9 (dilution, 1:1,000; cat. no., 9504) and actin (dilution, 1:1,000; cat. no., 8456) primary antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA). All the primary antibodies were incubated at room temperature for 4 h prior to washing with TBS-Tween. Next, membranes were incubated with a goat anti-rabbit horseradish peroxidase-conjugated IgG secondary antibody (dilution, 1:1,000; cat. no., SA00001-2; ProteinTech Group, Inc.) at room temperature for 1 h. Proteins were detected using an enhanced chemiluminescence kit (cat. no. 120702-74; Advansta, Inc., Menlo Park, CA, USA). The Syngene Bio Imaging system (GeneGnome HR, Synoptics Ltd., Cambridge, UK) was used to capture the images. And the Image-Pro Plus (Media Cybernetics, Inc., Rockville, MD, USA) was used to quantify the protein expression.

Statistical analysis. All data are presented as the mean \pm standard deviation. SPSS 19.0 (IBM Corp., Armonk, NY, USA) was used to perform one-way analysis of variance and the least significant difference test for multiple comparisons. $P < 0.05$ was considered to indicate a statistically significant difference.




Figure 1. The effects of different concentrations of paclitaxel and Zn on PC-3 cells were analyzed by MTT assays. Cells were treated with different concentrations of (A) Zn, and (B) paclitaxel for 48 h. (C) PC-3 cells were treated with 10 nmol/l paclitaxel combined with different concentrations of Zn for 48 h. Data are presented as the mean \pm standard deviation of triplicate experiments. * $P < 0.01$ vs. control. Zn, zinc.

Results

Zinc increases the sensitivity of PC-3 cells to paclitaxel. First, an MTT assay was used to determine the optimal concentration combination of zinc and paclitaxel. PC-3 cells were treated with different concentrations of zinc and paclitaxel for 48 h. The results showed that 0–250 $\mu\text{mol/l}$ zinc had no significant effect on PC-3 cells compared with untreated cells (Fig. 1A). However, zinc concentrations $>250 \mu\text{mol/l}$ significantly decreased the activity of PC-3 cells. PC-3-cell viability was reduced by $\sim 25\%$ by 10 nmol/l paclitaxel compared with untreated cells (Fig. 1B). The effect of a 48-h incubation with 10 nmol/l paclitaxel and different concentrations of zinc was investigated. Treatment with 10 nmol/l paclitaxel combined with 250 $\mu\text{mol/l}$ zinc reduced PC-3 cell proliferation by $\sim 50\%$ compared with untreated cells ($P < 0.05$; Fig. 1C). Therefore, 10 nmol/l paclitaxel combined with 250 $\mu\text{mol/l}$ zinc was used in subsequent experiments.

To explore the effect of zinc combined with paclitaxel on the proliferative ability of PC-3 cells, a clone formation assay was performed. The cell clone formation rate was significantly reduced in the cells treated with paclitaxel only or zinc combined with paclitaxel, compared with the control cells and cells treated with zinc only (Fig. 2A). Furthermore, the cell clone formation rate was significantly lower in cells treated with zinc combined with paclitaxel than those treated with paclitaxel only ($P < 0.05$; Fig. 2B). This suggested that zinc combined with paclitaxel significantly reduced the proliferation ability of PC-3 cells. Cell proliferation was further investigated by immunofluorescence staining of Ki-67, visualized by confocal microscopy (Fig. 3). Zinc combined with paclitaxel significantly decreased the expression of Ki-67 protein, suggesting significant inhibition of the proliferative ability of PC-3 cells.

Hoechst staining was used to analyze apoptosis (Fig. 3). Zinc combined with paclitaxel significantly enhanced the fluorescence intensity, and nuclear fragmentation was evident. This indicated that zinc combined with paclitaxel significantly induced PC-3 cell apoptosis ($P < 0.05$). Annexin V and PI staining and flow cytometry revealed that, compared with control treatment ($2.28 \pm 3.34\%$) and treatment with zinc only ($4.12 \pm 2.52\%$), treatment with paclitaxel alone ($12.48 \pm 4.34\%$) and zinc combined with paclitaxel ($36.30 \pm 3.68\%$) both increased the rate of PC-3-cell apoptosis, with the combination treatment having most significant effect ($P < 0.05$; Fig. 4A and B). These results suggested that zinc enhanced the sensitivity of PC-3 prostate cancer cells to paclitaxel chemotherapy.

A decrease in mitochondrial membrane potential is a key feature of early-stage apoptosis. A change in JC-1 fluorescence from red to green reflects a change in cell membrane potential. Flow cytometry was used to assess the effect of zinc combined with paclitaxel on the mitochondrial membrane potential of PC-3 cells (Fig. 5A). Treating cells with zinc combined with paclitaxel significantly decreased the ratio of red to green fluorescence ($P < 0.05$; Fig. 5B). This indicates that PC-3 cells treated with zinc and paclitaxel exhibited significantly reduced mitochondrial function compared with control cells, which may reflect early apoptosis. In summary, zinc combined with paclitaxel promoted apoptosis and inhibited cell proliferation. Hence, zinc increased the chemosensitivity of PC-3 cells to paclitaxel.

Zinc combined with paclitaxel induced the mitochondria-mediated apoptosis pathway. To investigate the mechanism by which zinc improved the sensitivity of PC-3 cells to paclitaxel chemotherapy, the mRNA levels of Bax, Bcl-2, caspase-3 and caspase-9 by RT-PCR (Fig. 6A) and the protein expression levels were analyzed by western blotting (Fig. 7A). There was a significant increase in the mRNA




Figure 2. The effect of Zn combined with paclitaxel on the clone-forming ability of PC-3 cells. (A) Images of the cells treated with 10 nmol/l paclitaxel and 250 μ mol/l Zn. (B) Quantification as the mean \pm standard deviation of triplicate experiments * P <0.05 vs. control; & P <0.05 vs. Zn; # P <0.05 vs. paclitaxel. Zn, zinc.




Figure 3. The effect of Zn combined with paclitaxel on apoptosis and proliferation assessed by immunofluorescence. PC-3 cells were stained with Hoechst 33342 and an anti-Ki-67 antibody. Changes in the cell nuclei and Ki-67 protein expression were detected. Zn, zinc.

and protein levels of cleaved caspase-3 and cleaved caspase-9 in PC-3 cells treated with paclitaxel alone and paclitaxel combined with zinc, compared with control cells or those treated with zinc alone (P <0.05; Figs. 6C and 7B). There was no significant change in protein levels of caspase-3 and

caspase-9 (Fig. 7B). There was also a significant decrease in the Bcl-2/Bax ratio (P <0.05; Figs. 6B and 7B). These results indicate that zinc improved the sensitivity of PC-3 cells to chemotherapy, possibly via effects on the mitochondria-mediated apoptosis pathway.




Figure 4. The effect of Zn combined with paclitaxel on PC-3-cell apoptosis. (A) Annexin V and propidium iodide staining were used to analyze apoptotic rate by flow cytometry. (B) Data are presented as the mean \pm standard deviation of triplicate experiments. [#]P<0.05 vs. control; [&]P<0.05 vs. Zn; [※]P<0.05 vs. paclitaxel. Zn, zinc.




Figure 5. The effect of Zn combined with paclitaxel on mitochondrial membrane potential in PC-3 cells. (A) Mitochondrial membrane potential was analyzed by flow cytometry. (B) The quantified results are presented as the mean \pm standard deviation of triplicate experiments [#]P<0.05 vs. control; [&]P<0.05 vs. Zn; [※]P<0.05 vs. paclitaxel. Zn, zinc.

Discussion

Current prostate cancer treatment comprises surgery, endocrine therapy, radiotherapy and chemotherapy. Seeing as prostate cancer is often diagnosed at a late stage, the optimal time for surgery is often missed (8,24), making effective chemotherapy important. Paclitaxel has been approved by the Food and Drug Administration as a first-line treatment for hormone-refractory

prostate cancer, and has been reported to be the only current drug that can prolong survival and improve quality of life in patients with tumors of the prostate (4,25). Paclitaxel has been widely used in the treatment of breast, ovarian, head and neck, and lung cancers. However, chemotherapy with a single drug has been associated with the development of drug resistance over time (9). Therefore, research based on chemotherapeutic combination strategies is important.




Figure 6. The effect of Zn combined with paclitaxel on apoptosis-associated gene expression levels. (A) The effect of Zn combined with paclitaxel on Bcl-2, Bax, caspase-3, caspase-9 mRNA levels in PC-3 cells, assessed by reverse transcription-polymerase chain reaction. (B) The ratio of Bcl-2/Bax was evidently different between different groups. (C) The gene expression levels of caspase-3 and caspase-9 have evident differences between different groups. The quantified results are presented as the mean \pm standard deviation of triplicate experiments $^{\#}P<0.05$ vs. control; $^{\&}P<0.05$ vs. Zn; $^*P<0.05$ vs. paclitaxel. Zn, zinc; Bax, Bcl-2 associated X, apoptosis regulator.




Figure 7. The effect of Zn combined with paclitaxel on apoptosis-associated protein expression levels. (A) Bcl-2, Bax, cleaved caspase-3, caspase-3, cleaved caspase-9 and caspase-9 protein levels were examined by western blotting. (B) The quantified results are presented as the mean \pm standard deviation of triplicate experiments $^{\#}P<0.05$ vs. control; $^{\&}P<0.05$ vs. Zn; $^*P<0.05$ vs. paclitaxel. Zn, zinc; Bax, Bcl-2 associated X, apoptosis regulator.

Functional p53 enhances the sensitivity of prostate cancer cells to chemotherapeutic agents, and loss of p53 function in the PC-3 prostate cancer cell line increases paclitaxel

resistance (26). Zinc deficiency is a cause of p53 mutation and inactivation (27). Zinc deficiency in prostate cells is closely associated with the occurrence and development of prostate

cancer (2,28). Zinc is an essential trace element for the function of ~200 enzymes in humans, thus serving an important role in genome stability and processes, including gene expression (9,20). Zinc concentrations have been demonstrated to be decreased by 60-70% in the serum and cancerous prostate tissue of patients with prostate cancer, and to decrease further as the cancer progresses (29). We speculate that the reduction in zinc concentration in prostate cancer may be associated with chemotherapy resistance. Therefore, in the present study, PC-3 prostate cancer cells were treated with zinc to investigate whether zinc could enhance sensitivity to chemotherapy.

Previous research has reported that physiological concentrations of zinc can directly induce apoptosis of prostate cancer cells via the mitochondrial pathway. The main mechanism of this is the release of mitochondrial cytochrome *c* and the activation of caspase-3, which triggers apoptosis (20,30). In the mitochondria-mediated apoptosis pathway, in the presence of deoxyadenosine triphosphate, cytochrome *c* binds with and activates apoptotic protease activating factor-1 (Apaf-1), and this complex further combines with procaspase-9 to form an apoptosis complex that activates procaspase-9. Activated caspase-9 activates other caspases, including caspase-3, thus inducing apoptosis (31). The Bcl-2 gene family serves an important role in this pathway. Some death receptor-independent stimuli (including ultraviolet ray irradiation and chemotherapy) activate the Bcl-2 gene family. Bcl-2 regulates the opening and closing of the permeability transition pore (32,33). To study the mechanism by which zinc enhances the chemotherapeutic effectiveness of paclitaxel, the expression of apoptosis-associated proteins was investigated by western blotting. The results indicate that the mechanism may involve a decrease in Bcl-2 protein expression levels, and an increase in Bax, cleaved caspase-3 and cleaved caspase-9 protein expression levels (Fig. 7). It is likely that the mitochondria-mediated apoptosis pathway was activated, causing apoptosis via activation of caspases by a cascade reaction.

Although single-agent chemotherapy can have a therapeutic effect against prostate cancer, patients with prostate cancer patients are prone to chemotherapy resistance. This is possibly due to severe zinc deficiency in prostate cancer tissues. The present study suggests that zinc enhances the sensitivity of the PC-3 prostate cancer cell line to the chemotherapeutic agent, paclitaxel. Combining paclitaxel with zinc enhanced therapeutic efficacy, and may have potential for overcoming issues associated with single-agent treatment. The present study provides a basis for novel strategies for tumor combination therapy.

Acknowledgements

We are grateful to Ruth Tunn, PhD, for editing the English text of a draft of this manuscript.

Funding

The present study was supported by the Research Fund of the National Natural Science Foundation of China (grant nos. 81572927, 81501982, 81772794, 81472419 and 81672948), the Jilin Province Research Foundation for the Development of Science and Technology Project (grant nos. 20150414025GH,

20170623021TC and 20160414005GH) and the Jilin University Bethune Plan B Projects (grant no., 2015222).

Availability of data and materials

Some datasets are not available as the experimental group is still performing further studies. However, other data is available from the corresponding author on reasonable request.

Authors' contributions

YLi, YLiu, LS and PZ participated in the research design. PZ, XT, HG, JL and RG conducted the experiments and contributed to data acquisition and analysis. PZ, JS and YYC performed the data analysis. PZ and YLiu contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. *Lancet* 387: 70-82, 2016.
- Lavery HJ and Cooperberg MR: Clinically localized prostate cancer in 2017: A review of comparative effectiveness. *Urol Oncol* 35: 40-41, 2017.
- Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A and Blandino G: Mutant p53: An oncogenic transcription factor. *Oncogene* 26: 2212-2219, 2007.
- Gan L, Wang J, Xu H and Yang X: Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. *Prostate* 71: 1158-1166, 2011.
- Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC and Fojo T: A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. *Proc Natl Acad Sci USA* 97: 2904-2909, 2000.
- Li Y, Mizokami A, Izumi K, Narimoto K, Shima T, Zhang J, Dai J, Keller ET and Namiki M: CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. *Prostate* 70: 48-60, 2010.
- Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M and Getzenberg RH: Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. *J Cell Biochem* 112: 2125-2137, 2011.
- Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET and Namiki M: The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. *Prostate* 67: 955-967, 2007.
- Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y and Huang H: Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. *Cancer Res* 69: 8386-8394, 2009.
- Ting HJ, Hsu J, Bao BY and Lee YF: Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. *Cancer Lett* 247: 122-129, 2007.

11. Ding WQ, Yu HJ and Lind SE: Zinc-binding compounds induce cancer cell death via distinct modes of action. *Cancer Lett* 271: 251-259, 2008.
12. Kim S, Seo JW, Oh SB, Kim SH, Kim I, Suh N and Lee JY: Disparate roles of zinc in chemical hypoxia-induced neuronal death. *Front Cell Neurosci* 9: 1, 2015.
13. Zhao Y, Tan Y, Dai J, Wang B, Li B, Guo L, Cui J, Wang G, Li W and Cai L: Zinc deficiency exacerbates diabetic down-regulation of Akt expression and function in the testis: Essential roles of PTEN, PTP1B and TRB3. *J Nutr Biochem* 23: 1018-1026, 2012.
14. Kayatekin C, Zitzewitz JA and Matthews CR: Zinc binding modulates the entire folding free energy surface of human Cu,Zn superoxide dismutase. *J Mol Biol* 384: 540-555, 2008.
15. Fanzo JC, Reaves SK, Cui L, Zhu L, Wu JY, Wang YR and Lei KY: Zinc status affects *p53*, *gadd45*, and *c-fos* expression and caspase-3 activity in human bronchial epithelial cells. *Am J Physiol Cell Physiol* 281: C751-C757, 2001.
16. Kelleher SL, McCormick NH, Velasquez V and Lopez V: Zinc in specialized secretory tissues: Roles in the pancreas, prostate, and mammary gland. *Adv Nutr* 2: 101-111, 2011.
17. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, Jacob-Hirsch J, Gelernter I, Harmelin A, Barshack I, *et al*: Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. *Int J Cancer* 131: E562-E568, 2012.
18. Kloubert V and Rink L: Zinc as a micronutrient and its preventive role of oxidative damage in cells. *Food Funct* 6: 3195-3204, 2015.
19. Carraway RE and Dobner PR: Zinc pyrithione induces ERK- and PKC-dependent necrosis distinct from TPEN-induced apoptosis in prostate cancer cells. *Biochim Biophys Acta* 1823: 544-557, 2012.
20. Gallus S, Foschi R, Negri E, Talamini R, Franceschi S, Montella M, Ramazzotti V, Tavani A, Dal Maso L and La Vecchia C: Dietary zinc and prostate cancer risk: A case-control study from Italy. *Eur Urol* 52: 1052-1056, 2007.
21. Seth R, Corniola RS, Gower-Winter SD, Morgan TJ Jr, Bishop B and Levenson CW: Zinc deficiency induces apoptosis via mitochondrial p53- and caspase-dependent pathways in human neuronal precursor cells. *J Trace Elem Med Biol* 30: 59-65, 2015.
22. Gu J, Wang B, Liu Y, Zhong L, Tang Y, Guo H, Jiang T, Wang L, Li Y and Cai L: *Murine double minute 2* siRNA and wild-type *p53* gene therapy interact positively with zinc on prostate tumours in vitro and in vivo. *Eur J Cancer* 50: 1184-1194, 2014.
23. Shao Y, Liu Y, Shao C, Hu J, Li X, Li F, Zhang L, Zhao D, Sun L, Zhao X, *et al*: Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. *Cancer Gene Ther* 17: 844-854, 2010.
24. Bataineh ZM, Bani Hani IH and Al-Alami JR: Zinc in normal and pathological human prostate gland. *Saudi Med J* 23: 218-220, 2002.
25. Wang C, Huang SB, Yang MC, Lin YT, Chu IH, Shen YN, Chiu YH, Hung SH, Kang L, Hong YR, *et al*: Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. *PLoS One* 10: e0120913, 2015.
26. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW and Gao AC: Functional p53 determines docetaxel sensitivity in prostate cancer cells. *Prostate* 73: 418-427, 2013.
27. Krone CA and Harms LC: Re: Zinc supplement use and risk of prostate cancer. *J Natl Cancer Inst* 95: 1556-1557, 2003.
28. Costello LC and Franklin RB: The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. *Mol Cancer* 5: 17, 2006.
29. Stepien M, Hughes DJ, Hybsier S, Bamia C, Tjonneland A, Overvad K, Affret A, His M, Boutron-Ruault MC, Katzke V, *et al*: Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. *Br J Cancer* 116: 688-696, 2017.
30. Costello LC, Franklin RB and Feng P: Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. *Mitochondrion* 5: 143-153, 2005.
31. Yang Y, Zong M, Xu W, Zhang Y, Wang B, Yang M and Tao L: Natural pyrethrins induces apoptosis in human hepatocyte cells via Bax- and Bcl-2-mediated mitochondrial pathway. *Chem Biol Interact* 262: 38-45, 2017.
32. Shan M and Fan TJ: Cytotoxicity of carteolol to human corneal epithelial cells by inducing apoptosis via triggering the Bcl-2 family protein-mediated mitochondrial pro-apoptotic pathway. *Toxicol In Vitro* 35: 36-42, 2016.
33. Gibson CJ and Davids MS: BCL-2 Antagonism to target the intrinsic mitochondrial pathway of apoptosis. *Clin Cancer Res* 21: 5021-5029, 2015.